PDCD1 and classic Hodgkin lymphoma: Combined inhibition of PD1/PD-L1- and CTLA4-mediated suppression in cHL was hypothesed by the finding that CTLA4 significantly increased during treatment with nivolumab and ipilimumab, and remained so after the end of treatment with this drug [117].